The Opioid Settlement Left the Sackler Family With $6 Billion and No Criminal Convictions
Problem Definition
Purdue Pharma's internal documents — produced in the 2007 federal guilty plea and expanded through the Massachusetts AG's 2019 litigation — show that the company received field reports of OxyContin's 12-hour dosing failure, responded by instructing sales representatives to recommend dose increases rather than correcting the dosing claim, and marketed the drug using a misrepresented addiction risk figure derived from a five-sentence letter about hospitalized patients.
Approximately 247,000 people died from prescription opioid overdoses between 1999 and 2019. The Sackler family received $10-12 billion in distributions from Purdue during the period of peak OxyContin revenue. The bankruptcy settlement required the Sacklers to pay approximately $6 billion — less than half of what they received — and provided broad civil liability releases.
No member of the Sackler family has been criminally convicted. Richard Sackler patented a buprenorphine formulation for opioid addiction treatment in 2018, while litigation was active. The settlement is final. The accountability gap is structural.
Root Causes
Corporate criminal liability in the US pharmaceutical industry operates primarily through entity-level guilty pleas that do not expose individual executives to personal criminal accountability
Bankruptcy proceedings that include civil liability releases allow mass-tort defendants to cap total exposure below the value already extracted, rewarding asset distribution prior to litigation
The FDA's prescription opioid approval and monitoring framework in the 1990s-2000s had no mechanism to detect or respond to systematic marketing misrepresentation of addiction risk